Paclitaxel · Abraxane, Paclitaxel Protein Bound Particles Albumin Bound

What is Paclitaxel?

Paclitaxel is a microtubule inhibitor that binds tubulin and stabilizes microtubules by preventing depolymerization, disrupting cell division. It also induces apoptosis by blocking Bcl-2.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Abraxane, Paclitaxel Protein Bound Particles Albumin Bound, Taxol, IP PTX

Drug type

Small molecule

Targets

tubulin, Bcl-2 (secondary target)

Mechanism

Inhibitor of tubulin

Pathways

microtubule stabilization, apoptosis

Therapy area

Oncology

Developer

Hq Spclt Pharma

In trials of

ACHV, CELC, SMMT

FDA status

Approved as Abraxane, Paclitaxel Protein Bound Particles Albumin Bound, Taxol (December 29, 1992), NDA020262 · FDA label

✅ FDA-approved uses

• Metastatic breast cancer (Abraxane)
• Locally advanced or metastatic non-small cell lung cancer (Abraxane)
• Metastatic adenocarcinoma of the pancreas (Abraxane)

From the indications section of the FDA label (version of Oct 31, 2022). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Appendiceal AdenocarcinomaHigh Grade MetastaticIntraperitonealIvonescimabPaclitaxelPhase IIBreast CancerBreast NeoplasmHER2-negative Breast Cancer

Sources

• FDA label (DailyMed)
• FDA label Paclitaxel (2023-11-01), indications
• FDA label Paclitaxel Protein Bound Particles Albumin Bound (2023-05-01), indications
• FDA label Abraxane (2022-10-31), indications
• NCI Thesaurus
• ClinicalTrials.gov NCT03412643

Updated Oct 3, 2026.